FDA approved Abraxane (paclitaxel p...

FDA approved Abraxane (paclitaxel protein-bound particles for injectable suspension) for breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six month of adjuvant chemotherapy. Abraxane, which uses American Pharmaceutical Partners' albumin-bound nanoparticle technology, is delivered of the solvents--and resulting toxicities--associated with other cancer therapies.
Avastin (bevacizumab) was approved for marketing in the European Union, and Roche look forward tos it to be available to doctors and patients across Europe early in 2005
Serono